Infliximab (Remicade®) is a chimeric (mouse/human) IgG1 monoclonal antibody. Like Etanercept and Adalimumab, Infliximab's is a TNFa blocker. Infliximab is used for treatment of a variety of autoimmune diseases, e.g. Crohn's disease, ulcerative colitis and rheumatoid arthritis. It is composed of human constant and murine variable regions with an approximate molecular weight of 149,1 kDa. The patent for the monoclonal TNF-alpha antibody Infliximab (Remicade®) expired at the beginning of 2015.

Protagen has considerable experience in the analysis of different variants of Remicade originators and biosimilars.

To support the analytical development of Remicade biosimilars or biobetters, Protagen has set up an analysis program in accordance with ICH Q6B guidelines, including method setup, validation of customer-specific methods, and release testing. This package includes protein quantification, characterizing the protein primary structure, analysis of N- glycosylation and protein modifications.

Specific BioAssay provided by a strategic partner:

  • Target: Inhibition of TNF-α signaling    Assay type: Proliferation Assay, statistical analysis by 4 parameter fit or PLA


Your contact for Infliximab at Protagen Protein Services GmbH

Martin-Blueggel 150x100px

Martin Blüggel

Chief Executive Officer (CEO)
Our business development team will be happy to assist you with your project.

Phone: +49 (0) 231 9742-6100